For research use only. Not for therapeutic Use.
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].
Tafasitamab (XmAb5574) induces cytotoxicity against Mino and Jeko (MCL) cell lines? in an E/T ratio-dependent manner. Tafasitamab (XmAb5574) increases ADCP and antiproliferative? activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2].
Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models[1].
| Catalog Number | I043253 |
| CAS Number | 1422527-84-1 |
| Purity | ≥95% |
| Reference | [1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29. [2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res |
